Becton, Dickinson and Company logo

    Becton, Dickinson and Company (BDX)

    Healthcare · Medical - Instruments & Supplies

    Market Closed · Opens in 1d 18h
    $149.31
    0.27 (0.00%)

    6-Month Price Action

    Key Stats

    Market Cap
    $54.09B
    P/E Ratio
    24.23
    EPS (TTM)
    $6.16
    Dividend Yield
    2.50%
    Day Range
    $147.19 – $150.19
    52W Range
    $127.59 – $187.35
    RSI (14)
    37.9
    Volume
    1,818,077

    Wall Street Price Target

    6 analysts
    Avg $172.85
    Now $149.31
    Low $159.00High $202.00

    Wall Street Consensus

    Moderate Buy8 recent ratings
    • Piper SandlerNeutral → Neutral
    • Piper SandlerNeutral → Neutral
    • Argus ResearchBuy → Buy
    • CitigroupBuy → Buy
    • CitigroupBuy → Buy
    • JP MorganNeutral → Neutral
    • JefferiesBuy → Buy
    • Piper SandlerNeutral → Neutral

    Becton, Dickinson and Company: Buy, Hold or Sell?

    Get the latest BDX trends, price moves, and analyst calls — free to your inbox.

    Free. Unsubscribe anytime.

    Terms · Privacy Policy

    About Becton, Dickinson and Company

    Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

    Data provided by Financial Modeling Prep. VonTrend is a financial publisher, not a financial advisor. Information is for educational purposes only and is not investment advice.